Obesity, metabolic dysfunction, and risk of kidney stone disease: a national cross-sectional study

References

• Sorokin I, Mamoulakis C, Miyazawa K, et al. Epidemiology of stone disease across the world. World J Urol. 2017;35(9):1301–1320.
   PubMed Web of Science ®Google Scholar
• Abufaraj M, Xu T, Cao C, et al. Prevalence and trends in kidney stone among adults in the USA: analyses of national health and nutrition examination survey 2007–2018 data. Euro Urol Focus. 2021;7(6):1468–1475.
   PubMedGoogle Scholar
• Zeng G, Mai Z, Xia S, et al. Prevalence of kidney stones in China: an ultrasonography based cross-sectional study. BJU Int. 2017;120(1):109–116.
   PubMed Web of Science ®Google Scholar
• Wang K, Ge J, Han W, et al. Risk factors for kidney stone disease recurrence: a comprehensive meta-analysis. BMC Urol. 2022;22(1):62.
   PubMed Web of Science ®Google Scholar
• Trinchieri A, Ostini F, Nespoli R, et al. A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol. 1999;162(1):27–30.
   PubMed Web of Science ®Google Scholar
• Chand RB, Shah AK, Pant DK, et al. Common site of urinary calculi in kidney, ureter and bladder region. Nepal Med Coll J. 2013;15(1):5–7.
   PubMedGoogle Scholar
• Rule AD, Lieske JC, Pais VM. Management of kidney stones in 2020. JAMA. 2020;323(19):1961–1962.
   PubMed Web of Science ®Google Scholar
• Lee YC, Huang SP, Juan YS, et al. Impact of metabolic syndrome and its components on kidney stone in aging Taiwanese males. Ag Male2016;19(3):197–201.
   PubMed Web of Science ®Google Scholar
• Boyd C, Wood K, Whitaker D, et al. The influence of metabolic syndrome and its components on the development of nephrolithiasis. Asian J Urol. 2018;5(4):215–222.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Zhang Y, Tan J, et al. The association between metabolic syndrome and lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males: evidence based on propensity score matching. Transl Androl Urol. 2021;10(1):384–396.
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Abbasi F, Lamendola C, et al. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med. 2007;167(7):642–648.
   PubMedGoogle Scholar
• Antoni KG, Antoni B, Uran I, et al. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male. 2020;23(5):1442–1454.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Zhang Y, Zhang F, et al. Prevalence and associated factors of metabolic syndrome in Chinese middle-aged and elderly population: a national cross-sectional study. Agi Male 2021;24(1):148–159.
   PubMed Web of Science ®Google Scholar
• Stefan N, Häring HU, Hu FB, et al. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diab Endocrinol. 2013;1(2):152–162.
   PubMed Web of Science ®Google Scholar
• Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Annals Int Med. 2013;159(11):758–769.
   PubMed Web of Science ®Google Scholar
• Cho YK, Lee J, Kim HS, et al. Impact of transition in metabolic health and obesity on the incident chronic kidney disease: a nationwide cohort study. J Clin Endocrinol Metab. 2020;105(3):dgaa033.
   Web of Science ®Google Scholar
• Hermoso DAM, Bizerra PFV, Constantin RP, et al. Association between metabolic syndrome, hepatic steatosis, and testosterone deficiency: evidences from studies with men and rodents. The Aging Male. 2020;23(5):1296–1315.
   PubMed Web of Science ®Google Scholar
• Liu W, Li W, Wang Z, et al. Metabolically abnormal obesity increases the risk of advanced prostate cancer in Chinese patients undergoing radical prostatectomy. Cancer Manag Res. 2020;12:1779–1787.
   PubMed Web of Science ®Google Scholar
• Pan K, Yao X, Liu M, et al. Association of serum uric acid status with bone mineral density in adolescents aged 12–19 years. Front Med. 2020;7:255.
   Web of Science ®Google Scholar
• Gilbride J. Review of anthropometric standardization reference manual. In T.G. Lohman, A.F. Roche and R. Martorell, editors. 1989. Journal of the American Dietetic Association; Vol. 89, No. 6. pp. 872, 874.
   Google Scholar
• Flegal K, Kit B, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. Jama. 2013;309(1):71–82.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640–1645.
   PubMed Web of Science ®Google Scholar
• Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. Jama. 2005;293(4):455–462.
   PubMed Web of Science ®Google Scholar
• Yoshimura E, Sawada SS, Lee IM, et al. Body mass index and kidney stones: a cohort study of Japanese men. J Epidemiol. 2016;26(3):131–136.
   PubMed Web of Science ®Google Scholar
• Feng X, Wu W, Zhao F, et al. Relationship between body mass index and kidney stones based on Dose-Response analyses using restricted cubic splines applied to NHANES 2011–2016 data. J Renal Nutrition 2021;31(3):263–269.
   PubMed Web of Science ®Google Scholar
• Phillips CM. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocrine Metab Disord. 2013;14(3):219–227.
   PubMed Web of Science ®Google Scholar
• Kim S, Chang Y, Yun KE, et al. Metabolically healthy and unhealthy obesity phenotypes and risk of renal stone: a cohort study. Int J Obes. 2019;43(4):852–861.
   Web of Science ®Google Scholar
• Sasaki Y, Kohjimoto Y, Iba A, et al. Weight loss intervention reduces the risk of kidney stone formation in a rat model of metabolic syndrome. Int J Urol 2015;22(4):404–409.
   PubMed Web of Science ®Google Scholar
• Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol. 2006;64(4):355–365.
   PubMed Web of Science ®Google Scholar
• İnanir M. Serum uric acid (SUA) in morbidly obese patients and its relationship with metabolic syndrome. Aging Male 2020;23(5):1165–1169.
   PubMed Web of Science ®Google Scholar
• DiBianco JM, Jarrett TW, Mufarrij P. Metabolic syndrome and nephrolithiasis risk: should the medical management of nephrolithiasis include the treatment of metabolic syndrome? Rev Urol. 2015;17(3):117–128.
   PubMedGoogle Scholar
• Aggarwal KP, Narula S, Kakkar M, et al. Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators. Biomed Res Int. 2013;2013:292953.
   PubMed Web of Science ®Google Scholar
• Wollin DA, Skolarikos A. Preminger GM: obesity and metabolic stone disease. Current Opinion in Urology. 2017;27(5):422–427.
   PubMed Web of Science ®Google Scholar
• Lieske JC. New insights regarding the interrelationship of obesity, diet, physical activity, and kidney stones. JASN. 2014;25(2):211–212.
   Web of Science ®Google Scholar
• Hood VL, Sternberg KM, de Waal D. Association of urine findings with metabolic syndrome traits in a population of patients with nephrolithiasis. Kidney360. 2022;3(2):317–324.
   PubMedGoogle Scholar
• Rahman IA, Nusaly IF, Syahrir S, et al. Association between metabolic syndrome components and the risk of developing nephrolithiasis: a systematic review and Bayesian meta-analysis. F1000Research. 2021;10:104.
   PubMedGoogle Scholar
• Yuan S, Larsson SC. Assessing causal associations of obesity and diabetes with kidney stones using Mendelian randomization analysis. Mol Genet Metab. 2021;134(1-2):212–215.
   PubMed Web of Science ®Google Scholar
• Medina JS, Rodríguez JC. A review of the pathophysiological factors involved in urological disease associated with metabolic syndrome. Actas Urológicas Espaolas. 2016;40(5):279–287.
   PubMed Web of Science ®Google Scholar
• Irina K, Sergey V, Igor B, et al. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. Aging Male 2019;22(4):241–249.
   PubMed Web of Science ®Google Scholar
• Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis. 2007;17(2):125–139.
   PubMed Web of Science ®Google Scholar